UNSPSC 51203401: Azathioprine

This classification denotes a purine antagonist and immunosuppressant with the molecular formula C9H6N7O2S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) AM94R510MS, chemically known as 6-1-methyl,4-nitro,5-imidazolyl mercaptopurine but more generally known as azathioprine sodium, which bears US NIH Compound Identifier 2265. European Medicines Agency schedules Azathioprine sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00641MIG.

Most nations, for tariff and trade purposes, schedule azathioprine under HS 29335995 and SITC 51576. As of Q4 2014, AZATHIOPRINE remains US FDA's Preferred Term for this commodity. Azathioprine bears US NLM identifiers UMLS ID C0004482 and NCI Concept Code C290. SMILES: CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-].

UNSPSC 51203401 Azathioprine, a Commodity code, does not align with the recent state and local procurement activity posted under this code. The four opportunities on record span pharmaceutical distribution programs, emergency medical supplies, and direct-to-manufacturer prescription initiatives—none of which involve azathioprine, an immunosuppressant medication used in organ transplant and autoimmune disease treatment. The mismatch suggests either a coding error in the state and local procurement systems tagging these opportunities or that azathioprine procurement through state and local channels is not currently being advertised under this code.

Recent activity under this code shows purchasing by health systems and state agencies pursuing broad pharmaceutical and medical supply agreements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026; the City of Tampa released an IFB for medical and first aid supplies for the Fire Department Rescue Division with a response deadline of March 13, 2026 and an estimated contract value of $700,000; the Texas Health and Human Services Commission posted an RFI on direct-to-manufacturer prescription programs with a response deadline of April 3, 2026; and Seminole County, Florida solicited naloxone and drug deactivation systems through an IFB with a July 26, 2023 deadline. The geographic footprint spans Florida, Texas, Minnesota, and Oregon. Given the absence of actual azathioprine procurement signals and the generic nature of the posted opportunities, this code does not present a clear procurement track record in state and local government.